Avidity Biosciences, Inc. (RNA)

26.45 +0.87 (+3.40%) 收市：04:00PM EDT

Avidity Biosciences, Inc.

10578 Science Center Drive
Suite 125
San Diego, CA 92121
United States
858 401 7900
https://www.aviditybiosciences.com

版塊: Healthcare
行業: Biotechnology
全職員工: 253

高階主管

名稱	頭銜	支付	行使價	出生年份
Ms. Sarah Boyce	President, CEO & Director	998.88k	1.16M	1972
Mr. Michael F. MacLean	Chief Financial & Chief Business Officer	674.74k	無	1966
Ms. Teresa McCarthy	Chief Human Resources Officer	628.79k	無	1964

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

公司管治

截至 2024年5月1日 止，Avidity Biosciences, Inc. 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：9；董事會：9；股東權利：8；現金賠償：8。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。